News

Video

Managing Symptoms, Controlling Disease With Radiation in Kidney Cancer

Fact checked by:

Key Takeaways

  • Radiation therapy is effective for symptom management in renal cell carcinoma, especially in bone or brain metastases, without invasive procedures.
  • It offers disease control by targeting resistant or slow-growing cancer sites, complementing drug therapies.
SHOW MORE

An expert explained how radiation may be a treatment option for patients with renal cell carcinoma to manage symptoms and control the disease.

Radiation may be an effective treatment option to manage symptoms and control disease in patients with renal cell carcinoma, a type of kidney cancer, an expert said.

CURE® spoke with Dr. Chad Tang at the 2024 ESMO Congress to learn more about the indications for which radiation may be considered in patients with renal cell carcinoma. Tang is an associate professor in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center in Houston.

Transcript:

I think there are two big categories for patients where radiation could be helpful. No. 1 is when a spot of cancer, such as in the bone or in the brain, is causing symptoms or threatening to cause symptoms such as close to the nerve routes in the spine. Radiation is minimally invasive. There won’t be any cutting or poking or prodding of the patient, so you can easily and effectively apply their radiation therapy sequenced with whatever drug therapy your medical oncologist has you on to alleviate or prevent the symptoms from recurring. That’s one category.

The second category is controlling the disease. Renal cell carcinoma is a disease that is known to evolve a lot. So different sites to the body can be very different genetically than other sites. And sometimes they evolve in a way that makes them resistant to the drug therapy or they’re so slow in their growth. In those instances, when it’s just a local site that’s causing problems because it’s resistant or only the site growing, we can take care of that site with radiation therapy, often with a very short course, and give you more time on the current drug that your medical oncologist has you on or buy you time off the drug.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Related Content